Analyst Reco. AnaptysBio, Inc.

Equities

ANAB

US0327241065

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-31 pm EDT			5-day change	1st Jan Change
23.95 ^USD	+1.27%		+0.17%	+11.81%

May. 09	AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	Apr. 16	MT
Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	Apr. 11	MT
JPMorgan Adjusts Price Target on AnaptysBio to $28 From $30, Maintains Neutral Rating	Apr. 01	MT
Wedbush Upgrades AnaptysBio to Outperform From Neutral, Says Derivative, Clinical Catalysts to Drive Shares Higher; Raises PT to $34 From $20	Mar. 12	MT
BTIG Initiates Coverage on AnaptysBio With Buy Rating, $55 Price Target	Feb. 26	MT
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating	Feb. 16	MT
Piper Sandler Initiates AnaptysBio at Overweight Rating With $80 Price Target	Feb. 16	MT
Wedbush Lifts AnaptysBio's PT to $20 From $18 Due to Updated Cash Guidance, Keeps Neutral Rating	Nov. 03	MT
UBS Cuts AnaptysBio Price Target to $21 From $28, Maintains Neutral Rating	Nov. 01	MT
Wedbush Lowers AnaptysBio's PT to $18 From $26, Adjusts Launch Estimates, Addition of Ulcerative Colitis for Rosnilimab; Keeps Neutral Rating	23-10-26	MT
Wedbush Lowers AnaptysBio's Price Target to $26 From $29, Keeps Neutral Rating	23-08-08	MT
JPMorgan Upgrades AnaptysBio to Neutral From Underweight, Trims Price Target to $30 From $31	23-05-22	MT
Guggenheim Adjusts AnaptysBio Price Target to $45 From $44, Maintains Buy Rating	23-05-12	MT
JPMorgan Adjusts Price Target on AnaptysBio to $31 From $32, Keeps Underweight Rating	23-04-12	MT
Raymond James Downgrades AnaptysBio to Market Perform From Outperform	23-01-06	MT
Wedbush Lowers AnaptysBio's PT to $29 From $32, Removes Valuations for Rosnilimab in Rheumatoid Arthritis, ANB032 in Atopic Dermatitis; Keeps Neutral Rating	23-01-06	MT
JPMorgan Adjusts Price Target on AnaptysBio to $32 From $24, Maintains Underweight Rating	22-11-18	MT
Raymond James Raises Price Target on AnaptysBio to $38 From $30, Maintains Outperform Rating	22-11-09	MT
Wedbush Raises AnaptysBio's PT to $32 From $21, Changes Launch Estimate for Rosnilimab in Alopecia, Adjusts Cost of Capital; Keeps Neutral Rating	22-11-09	MT
Guggenheim Upgrades AnaptysBio to Buy Rating From Neutral	22-11-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AnaptysBio, Inc.

Equities

ANAB

US0327241065

Analyst Reco.

Filters